Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

In A Chemical Library, Yale Researchers Find Keys To Cell Movement
Rummaging through a biotechnology company"s chemical closet, Yale University researchers found two molecules that will allow scientists to better study how cells move. The study in the journal Nature, published online Aug. 2, describes how two small molecules discovered by Cytokinetics Inc. block the action of a key complex that directs the assembly of actin filaments, which produce the force to help cells move. The target of these inhibitors is the Arp2/3 complex, a cellular component so vital that cells die without it. This dependence has made it challenging to learn exactly which cellular processes depend upon the complex.
generic viagra online
Children's Hospital Oakland Scientists First To Discover New For Harvesting Stem Cells
A groundbreaking study conducted by Children"s Hospital & Research Center Oakland is the first to reveal a new avenue for harvesting stem cells from a woman"s placenta, or more specifically the discarded placentas of healthy newborns. The study also finds there are far more stem cells in placentas than in umbilical cord blood, and they can be safely extracted for transplantation. Furthermore, it is highly likely that placental stem cells, like umbilical cord blood and bone marrow stem cells, can be used to cure chronic blood-related disorders such as sickle cell disease, thalassemia, and leukemia.
News of the day
City University London Joins Forces With Linking London And Six London Institutions To Improve Access To Nursing Courses, UK
Students wishing to pursue a career in nursing will have a helping hand thanks to an innovative partnership between City University London, five London colleges and one other university, in an agreement brokered by Linking London, a Lifelong Learning Network. The partners have signed a unique Progression Agreement which facilitates student progression, from Access Diploma courses and Certificates of Higher Education, to studying adult nursing at City University"s School of Community and Health Sciences.
Nutrition

Pluristem Therapeutics Receives European Regulatory Approval For Placental-Derived Stem Cell Clinical Trial

Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX: PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that the Paul Ehrlich Institute (PEI), the German competent authority in the European Union, has approved the Company"s Clinical Trial Application (CTA) and granted approval to begin clinical trials with its placental-derived adherent stromal cell product, termed PLX-PAD, for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD). In addition, Pluristem has already received approval from the Ethics Committee and, as previously announced, the US Food & Drug Administration (FDA) had cleared the Company"s Investigational New Drug (IND) application to initiate a similar trial in the United States. Both approvals of the CTA and IND clear the way for the world"s "first-in-man" clinical trial using PLX-PAD. Pluristem"s placental-derived stem cells are expanded using the company"s proprietary 3D PluriX™ technology. PLX-PAD is an off-the-shelf, one-size-fits-all product that needs no tissue matching prior to being administered to patients. In these phase I trials, to be conducted at multiple locations in the US and Germany, PLX-PAD will be administered to patients considered "late stage" that have not responded to traditional medical or surgical interventions. Zami Aberman, Chairman, President and CEO of Pluristem stated: "Administering the first allogeneic stem cell product in Germany, Pluristem will be using PLX-PAD, our first product candidate in our cell therapy pipeline. Additionally, should the clinical trials in the US and Europe prove successful, it will have been the first time adult stem cells, derived from placenta and grown using our proprietary technology, have been administered to humans safely. Because our PLX cells are an off-the-shelf, one-size-fits-all product that needs no tissue matching prior to being administered to patients, we believe this unique approach can provide patients with an affordable, immediate of cell therapy. We believe all this positions Pluristem as a leader in the cell therapy field." Professor Doctor Hans-Dieter Volk, Chairman of Charitç©-Universitaetsmedizin Berlin, Institute of Medical Immunology, and Chairman of the Berlin-Brandenburg Center for Regenerative Therapy (BCRT) stated: "Pluristem"s unique approach of implementing the placenta as the for cell therapy can potentially be the key to future treatments that may help millions of patients. We at the BCRT believe that regenerative therapy using placental-derived cells has the potential to become the superior for allogeneic cellular therapy." About Critical Limb Ischemia In the US alone, it is estimated that 8-12 million people suffer from critical limb ischemia associated with PAD. The disease is characterized by narrowing and hardening of the arteries in the patient"s limb(s) caused and/or aggravated by diabetes, Buerger"s Disease, other diseases and smoking. With decreased blood flow to the affected extremity, patients can suffer a host of complications including nerve and tissue damage. In advanced stages, critical limb ischemia can lead to gangrene, which often requires treatment with amputation. The disease is associated with a high rate of mortality and the need for frequent hospitalization from surgical complications. Pluristem Therapeutics Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009